Home › Endometrial Cancer › Missouri › St. Louis
Endometrial Cancer clinical trials in St. Louis, MO
29 studies for Endometrial Cancer are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Washington University School of Medicine, St Louis
- Cancer Care Center of O'Fallon, O'Fallon · 16 mi away
- HSHS Saint Elizabeth's Hospital, O'Fallon · 16 mi away
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- and 6 more
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Washington University Medicine, St Louis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- Washington University, School of Medicine, St Louis
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RecruitingPhase 2
- Washington University School of Medicine, St Louis
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RecruitingPhase 1
- Research Site, St Louis
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecruitingPhase 2
- Washington University School of Medicine, St Louis
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RecruitingPhase 1
- Washington University, St Louis
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RecruitingPhase 1/2
- Washington Univ. School of Medicine, St Louis
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RecruitingPhase 1/2
- Research Site, St Louis
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
RecruitingPhase 3
- Washington University School of Medicine, St Louis
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, St Louis
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RecruitingPhase 1
- Washington University School of Medicine - Siteman Cancer Center, St Louis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Washington University School of Medicine, St Louis
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RecruitingPhase 1
- Washington University, Siteman Cancer Center, St Louis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RecruitingPhase 1
- Normunity Investigational Site, St Louis
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Washington University School of Medicine, St Louis
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Washington University, St Louis
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Investigative Site #110, St Louis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RecruitingPhase 2
- 521, St Louis
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Washington University, St Louis
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
RecruitingObservational study
- Mercy Hospital - South, St Louis
- Mercy Hospital -STL, St Louis
A Study of LY4175408 in Participants With Advanced Cancer
RecruitingPhase 1
- Washington University, St Louis
Uterine Preservation Via Lifestyle Transformation
RecruitingPhase 2
- Washington University School of Medicine, St Louis
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RecruitingPhase 1
- Washington University Medical Campus, St Louis
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
RecruitingPhase 1
- Washington University School of Medicine, St Louis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, St Louis
Mindfulness in Endometrial and Cervical Cancer
RecruitingHealthy volunteers welcome
- Saint Louis University, St Louis
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
RecruitingPhase 2/3
- Washington University School of Medicine, St Louis
Endometrial Cancer trials in other cities
- Houston, TX68 studies
- New York City, NY52 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN38 studies
- Los Angeles, CA34 studies
- Philadelphia, PA28 studies
- San Antonio, TX27 studies
- Columbus, OH25 studies
- Oklahoma City, OK25 studies
- Chicago, IL25 studies
- Queens, NY25 studies
Other studies in St. Louis
- Non-Small Cell Lung Cancer73 studies
- Breast Cancer64 studies
- Metastatic Cancer54 studies
- Colorectal Cancer50 studies
- Cancer (all types)46 studies
- Prostate Cancer46 studies
- Lung Cancer39 studies
- Ovarian Cancer38 studies
- Pancreatic Cancer33 studies
- Head and Neck Squamous Cell Carcinoma28 studies
- Heart Failure26 studies
- Obesity25 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.